skip to main content
Idioma:
Mostrar Somente
Refinado por: Base de dados/Biblioteca: HighWire Press (Free Journals) remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Woyach, Jennifer A. ; Flinn, Ian W. ; Awan, Farrukh T. ; Eradat, Herbert ; Brander, Danielle ; Tees, Michael ; Parikh, Sameer A. ; Phillips, Tycel J. ; Ghori, Razi ; Reddy, Nishitha M. ; Farooqui, Mohammed Z.H. ; Byrd, John C. ; Stephens, Deborah M.

Blood, 2022-11, Vol.140 (Supplement 1), p.7004-7006 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
2
Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50
Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50

Frost, Nikolaj ; Ghori, Razi ; Roy, Ananya ; Nunes, Ana Tablante ; Yang, James Chih-Hsin

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT283-CT283 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study

Chung, Hyun Cheol ; Saada-Bouzid, Esma ; Muñoz, Federico Longo ; Yanez, Eduardo ; Im, Seock-Ah ; Castanon, Eduardo ; Graham, Donna M. ; Garcia-Corbacho, Javier ; Lopez, Juanita ; Ghori, Razi ; Dutcus, Corina ; Smith, Alan ; Norwood, Kevin ; Gomez-Roca, Carlos

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-07-PS12-07 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma

Woyach, Jennifer A ; Stephens, Deborah M ; Flinn, Ian W ; Bhat, Seema A ; Savage, Ronald E ; Chai, Feng ; Eathiraj, Sudharshan ; Reiff, Sean D ; Muhowski, Elizabeth M ; Granlund, Lindsey ; Szuszkiewicz, Lyndsey ; Wang, Wayne ; Schwartz, Brian ; Ghori, Razi ; Farooqui, Mohammed Z H ; Byrd, John C

Cancer discovery, 2024-01, Vol.14 (1), p.66-75

United States

Texto completo disponível

Citações Citado por

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.